ORIGINAL RESEARCH article
Front. Oncol.
Sec. Thoracic Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1611244
This article is part of the Research TopicInnovations in Biomarker-Based Lung Cancer ScreeningView all 13 articles
Methylation Detection in Percutaneous Lung Biopsy Preservation Fluid: A New Strategy to Improve Lung Cancer Diagnosis
Provisionally accepted
- 1Department of Thoracic Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China
- 2Department of Thoracic Surgery, Hebei Petro China Central Hospital, Langfang, Hebei Province, China
- 3The First hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Lung cancer, a major global health threat, has high incidence and mortality rates in China.Current diagnostic methods face challenges, especially in obtaining sufficient tissue samples for accurate diagnosis. This study aimed to develop a new strategy using percutaneous lung biopsy preservation fluid for gene methylation detection. A total of 182 patients who underwent percutaneous lung biopsy were included. The preservation fluid was replaced with a formalin -free solution for sample collection. DNA was extracted for methylation detection of SHOX2 and RASSF1A genes. The results showed that the DNA concentration qualification rate of the preservation fluid was 98.4%, and the internal reference Ct value qualification rate was 97.6%. New Cut -off values were established (△CtSHOX2 = 6.16, △CtRASSF1A = 6.85). The combined methylation detection had a sensitivity of 92.8% and a specificity of 94.7%. When combined with traditional morphological pathology, the sensitivity increased to 96.0%. The methylation detection was more sensitive than traditional pathology, especially for early -stage and unclassified lung cancer patients. It also compensated for 82.6% of tissue pathology missed diagnoses. In patients with pulmonary tuberculosis, the combined methylation detection showed 75.0% sensitivity in diagnosing tuberculosis complicated with lung cancer. In conclusion, methylation detection in percutaneous lung biopsy preservation fluid, combined with traditional pathology, can effectively reduce missed diagnoses and is worthy of further promotion.
Keywords: lung cancer, Percutaneous biopsy, preservation fluid, gene methylation, Diagnostic efficacy
Received: 14 Apr 2025; Accepted: 08 Jul 2025.
Copyright: © 2025 Yang, Feng, Tian, Yang, Wang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wenhao Wang, Department of Thoracic Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China
Huining Liu, Department of Thoracic Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.